Related Experiment Video
Updated: May 20, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Diona Gjermeni1, Sofia Szabó1, Viktoria Anfang1
1Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Clinical and Translational Science
|May 19, 2026
Summary
CYP2C19 genetic variations did not increase ischemic risk in atrial fibrillation patients undergoing PCI. However, poor/intermediate metabolizers showed a trend towards reduced bleeding, while low platelet reactivity was linked to major bleeding events.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Clinical Thrombosis
Background:
- CYP2C19 genetic polymorphisms influence clopidogrel's antiplatelet effect.
- This impacts ischemic and bleeding risks in patients undergoing percutaneous coronary intervention (PCI).
- Atrial fibrillation (AF) patients on oral anticoagulation (OAC) and clopidogrel require careful risk assessment.
Purpose of the Study:
- To evaluate the association of CYP2C19 genotype and platelet reactivity (PR) with ischemic and bleeding risks.
- Focus on AF patients undergoing PCI treated with OAC and clopidogrel.
- Assess outcomes including death, myocardial infarction (MI), stroke, and bleeding events.
Main Methods:
- Two-center prospective cohort study of 283 AF patients on OAC undergoing PCI.
- Classified patients into poor/intermediate metabolizers (PM/IM) and rapid metabolizers (RM) based on CYP2C19 LOF/GOF alleles.
- Assessed PR using thromboelastography (TEG) and/or multiple electrode aggregometry (MEA).
Main Results:
- PM/IM status (26%) was not significantly associated with the primary ischemic outcome (8.2% vs. 7.6%, p=0.869).
- Bleeding rates were numerically lower in PM/IM patients.
- High platelet reactivity (HPR) showed a trend towards increased ischemic risk (OR 2.005), while low platelet reactivity (LPR) was associated with major bleeding (OR 2.646, p=0.034).
Conclusions:
- CYP2C19 PM/IM status did not increase ischemic risk in this AF patient cohort.
- PM/IM status may offer protection against bleeding risk in AF patients undergoing PCI.
- HPR may indicate higher ischemic risk, whereas LPR is linked to major bleeding events.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...